ArticleOncogene2009
Inhibition of HPV-16 E7 oncogenic activity by HPV-16 E2.
Article in Oncogene, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Small Molecule Inhibitors of Human Papillomavirus: A Review of Research from 1997 to 2021.Current medicinal chemistry · 2024Review
- Salivary High-Risk Human Papillomavirus (HPV) DNA as a Biomarker for HPV-Driven Head and Neck Cancers.The Journal of molecular diagnostics : JMD · 2021Article
- Article
- Review
- The Interplay between Antiviral Signalling and Carcinogenesis in Human Papillomavirus Infections.Cancers · 2020Review
- The interaction between mitochondria and oncoviruses.Biochimica et biophysica acta. Molecular basis of disease · 2018Review
- Human Papillomavirus (HPV)-associated Oral Cancers and Treatment Strategies.Journal of dental research · 2014Review
- Regulation of the human papillomavirus type 16 late promoter by E7 and the cell cycle.Virology · 2013Article
- The transcriptional regulator gene E2 of the Human Papillomavirus (HPV) 16 influences the radiosensitivity of cervical keratinocytes.Radiation oncology (London, England) · 2012Article
- Type-specific interaction between human papillomavirus type 58 E2 protein and E7 protein inhibits E7-mediated oncogenicity.The Journal of general virology · 2012Article
- Nonconserved lysine residues attenuate the biological function of the low-risk human papillomavirus E7 protein.Journal of virology · 2011Article
- HPV16 E2 could act as down-regulator in cellular genes implicated in apoptosis, proliferation and cell differentiation.Virology journal · 2011Article
- A clinical overview of centrosome amplification in human cancers.International journal of biological sciences · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Human papillomavirus (HPV) E7 is essential in inducing S-phase progression in differentiating epithelial cells. We have previously shown that HPV-16 E7 activity can be controlled by a direct interaction with the viral transcriptional activator E2, thereby inhibiting transforming potential of E7. We have extended these analyses to show that E2 induces a generalized re-localization of E7 within the cell nucleus, one potential consequence of which is the inhibition of E7-induced degradation of pRb. Most importantly, we show that E2 can also inhibit the ability of E7 to induce centrosome abnormalities, thus preventing aberrant mitoses. Taken together, these studies highlight the central importance of E2 in controlling the functions of E7, independently of the ability of E2 to regulate transcription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.